The startup develops drug therapeutics that utilize lipid nanoparticle engineering to induce antigen-specific immune tolerance in vivo. Their approach targets the underlying mechanisms of autoimmunity, allergies, and food sensitivities, enabling pharmaceutical companies to enhance their allergy treatment pipelines.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for autoimmune diseases, allergies, and food sensitivities often manage symptoms rather than addressing the underlying cause of immune dysregulation. Pharmaceutical companies need novel therapeutic approaches to enhance their pipelines for treating these conditions.
Solution
The startup is developing drug therapeutics based on lipid nanoparticle (LNP) engineering to induce antigen-specific immune tolerance in vivo. This technology aims to target the fundamental mechanisms driving autoimmunity, allergies, and food sensitivities, potentially leading to more effective and disease-modifying treatments. By encapsulating specific antigens within LNPs, the therapeutics can selectively modulate the immune response, promoting tolerance to the targeted antigen and preventing the aberrant immune reactions that characterize these diseases. This approach offers a platform for creating targeted therapies that can restore immune balance and provide long-term relief for patients.
Target Audience
The primary customers are pharmaceutical companies seeking to expand their pipelines with innovative allergy and autoimmune disease treatments.
Features
- Lipid nanoparticle (LNP) delivery system for targeted antigen presentation
- Induction of antigen-specific immune tolerance in vivo
- Modulation of the immune response to treat autoimmune diseases, allergies, and food sensitivities